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 Cystinosis as a clinical entity is a progres-
sive dysfunction of multiple organs caused 
by the accumulation of cystine in the lyso-
somes of all the cells in the body due to 
mutations in the ubiquitous gene  CTNS , 
encoding the lysosomal cystine trans-
porter protein cystinosin. 1 The most 
severe and most frequent form of cystino-
sis is the infantile form, also called neph-
ropathic cystinosis. Children consistently 
develop the syndrome of De Toni – Debr é –
 Fanconi at 6 – 8 months of age, character-
ized by a severe fluid and electrolyte 
disturbance, growth retardation, and rick-
ets. 2 Corneal cystine crystals are also a 
constant symptom; they appear during the 
fi rst decade of life, resulting in photopho-
bia and visual impairment. Th e progres-
sive cystine storage also leads to kidney 
failure, diabetes, myopathy, hypothy-
roidism, hypogonadism, and central ner-
vous system deterioration. However, the 
extent and pace of these defects vary 
among patients. 
 Cysteamine, which reduces the intra-
lysosomal cystine concentration, was fi rst 
used in the treatment of cystinosis in 1976 
and was approved by the US Food and 
Drug Administration in 1994. In cultured 
cells accumulating cystine and in patients ’ 
white blood cells, it undisputedly clears 
the cystine very efficiently. 3 However, 
cysteamine does not prevent the Fanconi 
syndrome even if started very early in life. 
Despite this, most publications on its 
impact on the late complications of cysti-
nosis have been very optimistic and have 
suggested that cysteamine may prevent 
organ damage. 4,5 Th us, some believed that 
this disease was cured. If complications 
were occurring in patients under treat-
ment, either poor compliance with the 
treatment or the age at which the patients 
started the treatment was blamed. Yes, 
both of these have an impact on cyste-
amine therapy, as Brodin-Sartorius and 
colleagues (this issue) show. 6 However, 
they also show that patients who started 
cysteamine therapy early in life and dem-
onstrated good compliance still developed 
late complications. Th e new reality is that 
cysteamine delays the disease ’ s progres-
sion but does not cure it. End-stage renal 
failure, as well as the other complications, 
is still occurring. Th us, publications such 
as the one by Brodin-Sartorius and col-
leagues 6 are important in demonstrating 
that cystinosis is still in need of new ther-
apies. 
 Th e study presented by Brodin-Sartorius 
and colleagues 6 included 86 cystinosis 
patients and clearly showed that end-stage 
renal disease (ESRD) was delayed in 
some patients who started cysteamine 
before 5 years of age, but also that the 
majority of them still developed ESRD 
before the age of 15 years, the mean age 
at the start of ESRD being 13.4 ± 4.8. 
According to the 2010 and 2011 annual 
reports of North American Pediatric Renal 
Trials and Collaborative Studies, 1.4 % of 
children on dialysis and 2.1 % with kidney 
transplants have cystinosis. 7 Both dialysis 
and transplantation have signifi cant nega-
tive health effects, and because of the 
severe shortage of donor organs, patients 
may wait three to six years for transplanta-
tion. Th us, the mortality and morbidity 
associated with renal failure are high 
enough to consider cystinosis uncured. 
Similarly, according to Brodin-Sartorius 
and colleagues ’ study, 6 hypothyroidism 
appeared by 15 years of age even when 
cysteamine was started before 5 years of 
age. Neither the age of occurrence of neu-
romuscular disorders nor that of diabetes 
was delayed when cysteamine was taken 
before 5 years of age, but both occurred in 
fewer patients at the time of the study. 
Another comprehensive study on the long-
term impact of cysteamine was performed 
by Gahl and colleagues on 100 individuals 
with nephropathic cystinosis, examined 
between 1985 and 2006. 4 Their study 
showed a decrease in the frequency of 
symptoms with increased time on cysteam-
ine. But still, 92 % of the patients in their 
cohort had received a kidney transplant, 
75 % of patients had hypothyroidism, 69 % 
had pulmonary dysfunction, 60 % had a 
swallowing abnormality, and 50 % had 
myopathy. Also, young people with cysti-
nosis are still dying; the cause of death is 
not well characterized and would neces-
sitate a comprehensive study. In the study 
by Brodin-Sartorius and colleagues, 6 27.9 % 
of patients died, at a mean age of 26.8; the 
cause of death was infection or neuromus-
cular complications such as respiratory 
distress or swallowing impairment. In 
Gahl and colleagues ’ study, 4 one-third of 
the patients died, at a mean age of 28.5 
years. In addition to the causes of death 
already mentioned, this study also attrib-
uted death to renal complications and gas-
trointestinal damage. 4 
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 What is life like with cystinosis? In 
meeting families with cystinosis, we real-
ized that this is an everyday fight, that 
cystinosis patients must take not only 
cysteamine every 6  h, but also many other 
drugs and supplements around the clock 
every day. Many of the children need a 
gastric tube to absorb and tolerate all these 
medications. And still they develop many 
complications and have frequent hospital 
visits. Th e question is, how we can gain a 
better idea of the status of health in patients 
taking cysteamine? Publications on a large 
cohort of patients such as Brodin-Sartorius 
and colleagues ’, 6 recapitulating years of 
medical follow-up, are important. The 
major problem with this study is that these 
data are based on reviews of medical 
records, and the mean age at the start of 
the therapy was 9.9 years, much later than 
most cystinosis patients start cysteamine 
today. Thus, a historical review might 
influence negatively the data reported. 
How can current data be collected and 
reported? Th e new Cure Cystinosis Inter-
national Registry (CCIR) could be a useful 
tool for this purpose. The CCIR uses a 
comprehensive questionnaire fi lled out 
online by patients or family members 
regarding the tolerance to cysteamine, 
their compliance, and the symptoms they 
are experiencing. 8 Th e weekly statistical 
analyses are available for professionals. To 
date, 230 patients have registered, 221 of 
them have been treated with cysteamine, 
and 83.2 % started cysteamine before 5 
years of age, an age shown to be critical by 
Brodin-Sartorius and colleagues. 6 Still, 
29.9 % of the patients who started cysteam-
ine early had at least one kidney transplant, 
78.2 % of those before the age of 16 years. 
In addition, 47.8 % of the patients who 
started cysteamine early experienced mus-
cle weakness, and 23.9 % hypothyroidism. 
Th ese current data on a large cohort of 
patients show again that ESRD and com-
plications are occurring even when 
cysteamine therapy is started early in life. 
In addition, cysteamine is challenging to 
take and diffi  cult to tolerate. Th e need for 
frequent doses (oral every 6  h plus eye 
drops once an hour) necessitates that med-
ications be carried for all activities, but the 
most signifi cant impact of the every-6-h 
dosing schedule is that cystinosis patients 
never sleep through the night. Cysteamine 
also has a number of undesirable side 
eff ects, such as persistent odor and halito-
sis, along with more severe side eff ects of 
vomiting and diarrhea that render its 
administration diffi  cult. 9 Some patients 
stop taking cysteamine because they can-
not tolerate it. Brodin-Sartorius and col-
leagues 6 report that 28 % of the patients in 
their study had extended periods without 
cysteamine. Th e CCIR reports that 7.8 % 
of the patients currently do not take 
cysteamine, 68.7 % of these because of the 
side eff ects and tolerance. Th e drug side 
eff ects and frequent dosing have a direct 
negative impact on the patients ’ and fami-
lies ’ quality of life. A comprehensive study 
in this area is necessary. 
 Why does cysteamine delay the compli-
cations of cystinosis but not prevent them? 
Cysteamine, by allowing cystine to exit the 
lysosomes, overcomes the major function 
of the missing cystinosin but does not 
replace cystinosin. Even if the level of cys-
tine in white blood cells is low, what is the 
impact of cysteamine therapy on the tis-
sues? Little is known about this, for obvi-
ous reasons, but data suggest that cystine 
storage in tissues is not completely cleared 
by cysteamine. 2,10 Moreover, the fact that 
cysteamine does not treat the proximal 
tubulopathy shows that the physiopathol-
ogy of cystinosis is more complicated than 
expected, and cystinosin may have other 
functions still to be identifi ed ( Figure 1 ). 
Gahl  et al. 4 have mentioned that signifi -
cantly more deaths and complications 
were observed in patients homozygous for 
the 57 – kb  CTNS deletion compared with 
patients with only mutations. Brodin-Sar-
torius and colleagues did not observe any 
signifi cant diff erence between these two 
groups in survival or appearance of the 
renal and extrarenal complications. 6 A 
more comprehensive study on genotype –
 phenotype correlation would be necessary, 
but in regard to years of clinical reports, 
this correlation is not evident, which sug-
gests the existence of modifier genes 
responsible for the broad range of pheno-
type in patients with or without cyste-
amine ( Figure 1 ). Th is could explain why, 
among patients who start cysteamine early 
and have good compliance, some will 
develop ESRD or other complications 
before 15 years of age and some will expe-
rience fewer symptoms, later in their lives. 
Th e existence of these genes that infl uence 
the phenotype of cystinosis is obvious in 
the diff erent mouse models of cystinosis 
that Antignac ’ s group generated. The 
 Ctns  – / –  mice on a mixed 129 / Sv × C57BL / 6 
genetic background did not have any renal 
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 Figure 1  |  Physiopathology of cystinosis. Cystinosis is a monogenic hereditary disease caused by 
mutations or deletions in the ubiquitous gene  CTNS . This gene encodes a seven-transmembrane 
lysosomal protein, which is a proton-driven cystine transporter. However, the physiopathology 
of cystinosis suggests that cystinosin has other functions and / or other genes influence the pace 
and extent of the disease. This could explain the high variability in age of the appearance and 
severity of the complications observed in patients taking cysteamine, which allows cystine to 
exit the lysosomes. ADP, adenosine diphosphate; ATP, adenosine triphosphate; P i , inorganic 
phosphate. 
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dysfunction, nor did the FVB / N pure-
background mice, whereas the  Ctns   −  /  −  
mice on a pure C57BL / 6 background 
developed renal dysfunction as early as 6 
months of age and end-stage renal failure 
by 15 months. 11 Th e identifi cation of these 
other genes that infl uence the severity of 
the disease in the context of cystinosis 
should be of high interest and would help 
to better understand the physiopathology 
of cystinosis and the high variability of 
symptoms even with cysteamine therapy. 
 What is the outlook for patients with 
cystinosis? A new, delayed-release formu-
lation of cysteamine (DR Cysteamine) is 
currently being developed by Raptor 
Pharmaceutical on the basis of a study 
conducted by Dohil  et al. 12 Th e company 
recently completed its pivotal, phase 3 
clinical study. Th is new formulation needs 
to be taken twice daily, so the patients will 
be able to sleep through the night, and it 
will reduce the gastrointestinal side eff ects. 
Th us, the patients ’ quality of life will be 
improved, but will the impact on the dis-
ease also be improved? Hematopoietic 
stem cell transplantation, which has a sig-
nifi cant therapeutic benefi t in the mouse 
model of cystinosis, 13,14 could be the next 
treatment for cystinosis. However, proof 
that cell therapy has the same benefi ts in 
patients as in mice still needs to be dem-
onstrated. 
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 Recipe for a new imaging 
biomarker: carefully combine 
target, reagent, and technology 
 Hisataka  Kobayashi 1 and  Peter L.  Choyke 1 
 A careful combination of biological targeting moieties (C3 fragments), 
imaging reagents (a small particle of iron oxide), and appropriate 
technology (T2-weighted magnetic resonance imaging) is the key to the 
successful development of an imaging agent for glomerulonephritis. 
This recipe applies to virtually any molecular imaging probe for the 
kidney and throughout the body. However, each organ and disease 
requires a unique combination of these three components in order to 
achieve success. 
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 Kidney biopsy is the traditional method 
of diagnosing glomerulonephritis. How-
ever, there is a growing understanding 
that noninvasive imaging biomarkers 
could replace, or at least reduce the need 
for, biopsy. Imaging has the advantage that 
it is noninvasive and, therefore, could 
be repeatedly used to evaluate disease 
status. Rapid progress has been made in 
molecular imaging, which makes possible 
targeted probes that could only be hypo-
thesized a decade ago. Nevertheless, in 
reality, there are few examples of success-
ful molecular probes for specifi c diseases. 
Even fewer have been reported with mag-
netic resonance imaging (MRI), despite its 
inherent advantage of not using ionizing 
radiation. Unfortunately, MRI suffers 
from lower sensitivity compared with 
radionuclide methods. Sargsyan  et al. 1 
(this issue) report the development of just 
such a new MRI biomarker and demon-
strate its utility in a lupus nephritis model. 
It uses a targeting agent for C3 activation 
